tirzepatide taken off market (Zepbound) FDA confirms tirzepatide shortage is

The regulator said anyone taking GLP-1 medicines should be alert to any signs of vision loss, stop taking the medicine and seek urgent medical attention if any changes were noted

Retatrutide (LY3437943) is Eli Lillys experimental triple-agonist drug that activates: GLP-1 (Glucagon-like peptide-1) reduces appetite and slows digestion GIP (Glucose-dependent insulinotropic peptide) enhances insulin sensitivity Glucagon receptor increases fat metabolism and energy expenditure In phase-2 trials, Retatrutide achieved up to 24% body-weight reduction rivaling or even surpassing bariatric surgery outcomes

Heres how they work: They reduce appetite: helping you feel full sooner and stay full longer They slow digestion: which stabilizes blood sugar and reduces overeating They act on the brain: lowering food noise and cravings Most GLP-1s are most commonly offered as injectables that you self-administer weekly

You Are Still in the Dose Adjustment Phase Many patients begin at a low dose that is not intended to fully suppress appetite